Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

Melanoma is the most common form of skin cancer, but for patients with advanced melanoma who no longer respond to standard immunotherapy, treatment options are painfully limited. Vanderbilt ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small ...

Two BRAF-targeted agents already used together in several solid tumors have won parallel regulatory support in Europe. In its March 2026 meeting, the European Medicines Agency’s Committee for ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes. Melanoma, the deadliest ...

New technologies and innovations are changing the future of melanoma care. Teledermatology and skin screening mobile apps aided by artificial intelligence (AI) diagnostic support could assist in ...